Aurobindo Pharma Limited — Others, 28-05-2025: Copy of Newspaper Publication

Aurobindo Pharma has announced a board meeting on May 29 to approve the financial results for the quarter and half-year. The company reported consolidated total income of ₹3,172 Cr and a net profit after tax of ₹508 Cr for the year. Standalone total income was ₹1,093 Cr with a profit after tax of ₹175 Cr. Earnings per share stood at ₹15.58 (consolidated) and ₹7.03 (standalone). This highlights healthy operational performance and consistent profitability, supporting confidence in the company’s earnings momentum.